Comparison of Clinical and Pathological Tumour Staging Following CDK4/6 Inhibitor-based Neoadjuvant Therapy in HR+/HER2- Breast Cancer
{{output}}
Objective: CDK4/6 inhibitors are an established component of systemic therapy for hormone receptor-positive (HR+)/HER2- breast cancer, with proven efficacy in combination with endocrine therapy in both advanced and early-stage di... ...
